Abstract: ObjectiveTo explore the expressional value of tumor associated macrophages(TAMs)and cytokines in the prognosis of triple-negative breast cancer(TNBC)．MethodsImmunohistochemistry(IHC)and S-P staining method were used to detect the TAMs marker CD68 expression in 48 TNBC samples．Expressions of key cytokines including interleukin-6(IL-6)，IL-10，IL-12，IL-1β，chemokine(C-C motif)ligand-5(CCL-5)and macrophage inflammatory protein-2(MIP-2)were quantified by RT-PCR and enzyme-linked immunosorbent assay(ELISA)．The correlation between CD68 expression and prognosis was analyzed．Results34 cases(70．8%)out of 48 TNBC samples appeared CD68-positive expression．Compared to low infiltrated samples，IL-6 and CCL-5 were up-regulated in the high infiltrated tumors samples(P ＜0．01)，but there was no statistical difference in other cytokines between low and high infiltrated tumor samples．The survival rate of high infiltrated tumor samples were lower than that of low infiltrated tumor sample(P ＜0．05)．ConclusionsThe expression of TAMs were up-regulated in most of TNBC patients after the surgery．Its expression suggested unfavorable prognosis especially in high-infiltrated group．Those tumors with more macrophage also had elevated expression of cytokine(IL-6)and chemotactic factor(CCL-5)，both of which have potency to be clinical index and drug target for TNBC．
王建国，李绍杰. 肿瘤相关巨噬细胞和细胞因子表达对三阴乳腺癌患者预后的影响[J]. 中国现代手术学杂志, 2017, 21(2): 85-89.
WANG Jian-guo，LI Shao-jie. The Expression of Tumor Associated Macrophages and Cytokines in the Triple-negative Breast Cancer Patients after the Surgery. Chinese Journal of Modern Operative Surgery, 2017, 21(2): 85-89.
［1]Youlden DR，Cramb SM，Dunn NA，et al．The descriptive epidemiology of female breast cancer:an international comparison of screening，incidence，survival and mortality［J]．Cancer Epidemiol，2012，36(3):237-248．doi:10．1016/j．canep．2012．02．007．|［2]Markkula A，Bromée A，Henningson M，et al．Given breast canc-er，does breast size matter?Data from a prospective breast cancer cohort［J]．Cancer Causes Control，2012，23(8):1307-1316．doi:10．1007/s10552-012-0008-9．|［3]Creighton CJ，Li X，Landis M，et al．Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features［J]．Proc Natl Acad Sci U S A，2009，106(33):13820-13825．doi:10．1073/pnas．0905718106．|［4]Hennessy BT，Gonzalez-Angulo AM，Stemke-Hale K，et al．Characterization of a naturally occurring breast cancer subset enriched inepithelial-to-mesenchymal transition and stem cell characteristics［J]．Cancer Res，2009，69(10):4116-4124．doi:10．1158/0008-5472．CAN-08-3441．|［5]Evers B，Drost R，Schut E，et al．Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281and cisplatin［J]．Clin Cancer Res，2008，14(12):3916-3925．doi:10．1158/1078-0432．CCR-07-4953．|［6]Markkula A，Hietala M，Henningson M，et al．Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort［J]．Cancer Prev Res(Phila)，2012，5(5):735-745．doi:10．1158/1940-6207．CAPR-11-0442．|［7]Lundin KB，Henningson M，Hietala M，et al．Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients［J]．Br J Cancer，2011，105(11):1676-83．doi:10．1038/bjc．2011．441．|［8]Smith AK，Conneely KN，Pace TW，et al．Epigenetic changes associated with inflammation in breast cancer patientstreated with chemotherapy［J]．Brain Behav Immun，2014，38:227-36．doi:10．1016/j．bbi．2014．02．010．|［9]Ambarus CA，Krausz S，van Eijk M，et al．Systematic validation of specific phenotypic markers for in vitro polarized humanmacrophages［J]．J Immunol Methods，2012，375(1-2):196-206．doi:10．1016/j．jim．2011．10．013．|［10]Multhoff G，Radons J．Radiation，inflammation，and immune responses in cancer［J]．Front Oncol，2012，2:58．doi:10．3389/fonc．2012．00058．eCollection 2012 Jun 4．|［11]Foulkes WD，Smith IE，Reis-Filho JS．Triple-negative breast cancer［J]．N Engl J Med，2010，363(20):1938-1948．doi:10．1056/NEJMra1001389．|［12]Su S，Liu Q，Chen J，et al．A positive feedback loop between mesenchymal-like cancer cells andmacrophages is essential to breast cancer metastasis［J]．Cancer Cell，2014，25(5):605-620．doi:10．1016/j．ccr．2014．03．021．|［13]Huang M，Wang L，Ma H，et al．Lack of an association between interleukin-6-174G/C polymorphism andcirculating interleukin-6 levels in normal population:a meta-analysis［J]．DNA Cell Biol，2013，32(11):654-664．doi:10．1089/dna．2013．2148．|［14]Hudis CA，Gianni L．Triple-negative breast cancer:an unmet medical need［J]．Oncologist，2011，16 Suppl 1:1-11．doi:10．1634/theoncologist．2011-S1-01．|［15]Tiainen S，Tumelius R，Rilla K，et al．High numbers of macrophages，especially M2-like(CD163-positive)，correlate withhyaluronan accumulation and poor outcome in breast cancer［J]．Histopathology，2015，66(6):873-83．doi:10．1111/his．12607．|［16]Stormes KA，Lemken CA，Lepre JV，et al．Inhibition of metastasis by inhibition of tumor-derived CCL5［J]．Breast Cancer Res Treat，2005，89(2):209-212．|［17]Ferrari N，Mohammed ZM，Nixon C，et al．Expression of RUNX1 correlates with poor patient prognosis in triple negativebreast cancer［J]．PLoS One，2014，9(6):e100759．doi:10．1371/journal．pone．0100759．eCollection 2014．|［18]Tyner JW，Bumm TG，Deininger J，et al．CYT387，a novel JAK2 inhibitor，induces hematologic responses and normalizesinflammatory cytokines in murine myeloproliferative neoplasms［J]．Blood，2010，115(25):5232-5240．doi:10．1182/blood-2009-05-223727．|［19]Pardanani A，Laborde RR，Lasho TL，et al．Safety and efficacy of CYT387，a JAK1 and JAK2 inhibitor，in myelofibrosis［J]．Leukemia，2013，27(6):1322-1327．doi:10．1038/leu．2013．71．|［20]Marotta LL，Almendro V，Marusyk A，et al．The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24-stemcelllike breast cancer cells in human tumors［J]．J Clin Invest，2011，121(7):2723-2735．doi:10．1172/JCI44745．|［21]Tiezzi DG，Valejo FA，Marana HR，et al．CD44+/CD24-cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast［J]．Med Oncol，2012，29(3):1479-1485．doi:10．1007/s12032-011-0014-x．|［22]Britschgi A，Andraos R，Brinkhaus H，et al．JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade:arationale for cotargeting these pathways in metastatic breast cancer［J]．Cancer Cell，2012，22(6):796-811．doi:10．1016/j．ccr．2012．10．023．|［23]Thomas S，Baumgart DC．Targeting leukocyte migration and adhesion in Crohn＇s disease and ulcerativecolitis［J]．Inflammopharmacology，2012，20(1):1-18．doi:10．1007/s10787-011-0104-6．|［24]Empana JP，Jouven X，CanouI-Poitrine F，et al．C-reactive protein，interleukin 6，fibrinogen and risk of sudden death in Europeanmiddle-aged men:the PRIME study［J]．Arterioscler Thromb Vasc Biol，2010，30(10):2047-2052．doi:10．1161/ATVBAHA．110．208785．|［25]Anderson DR，Poterucha JT，Mikuls TR，et al．IL-6 and its receptors in coronary artery disease and acute myocardial infarction［J]．Cytokine，2013，62(3):395-400．doi:10．1016/j．cyto．2013．03．020．
2017, Vol. 21 
